← All trials
NCT01948024
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2013
- Primary completion
- Aug 1, 2013
- Completion date
- Aug 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 57
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- bioRASI, LLCLead sponsor
- Sun PharmaceuticalsCollaborator
- Atlanta Center for Medical ResearchOverall official - principal investigator
- Advanced Pharma CR, LLCOverall official - principal investigator
- Compass ResearchOverall official - principal investigator
- Evolution Research GroupOverall official - principal investigator
- Collaborative Neuroscience NetworkOverall official - principal investigator
- New Hope Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.